Spyre Therapeutics, Inc. SYRE Derivative Liabilities (Non-Current)
Derivative Liabilities (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s derivative liabilities (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s derivative liabilities (non-current)?
- Spyre Therapeutics, Inc. (SYRE) reported derivative liabilities (non-current) of $6.69M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s derivative liabilities (non-current) changed year-over-year?
- Spyre Therapeutics, Inc.'s derivative liabilities (non-current) decreased by 59.4% year-over-year, from $16.49M to $6.69M.
- What does derivative liabilities (non-current) mean?
- Long-term financial obligations arising from derivative contracts that are not due within one year.
- How do you interpret derivative liabilities (non-current)?
- A decrease indicates a reduction in long-term financial risk, while an increase suggests growing long-term obligations related to financing.
- How does derivative liabilities (non-current) compare across companies?
- Typically found in companies with long-dated warrants or complex financing agreements that extend beyond the current fiscal year.